贝达喹啉在儿童和青少年耐多药结核病中的超说明书使用。
Off-Label Use of Bedaquiline in Children and Adolescents with Multidrug-Resistant Tuberculosis.
出版信息
Emerg Infect Dis. 2017 Oct;23(10):1711-3. doi: 10.3201/eid2310.170303. Epub 2017 Oct 17.
Abstract
We describe 27 children and adolescents <18 years of age who received bedaquiline during treatment for multidrug-resistant tuberculosis. We report good treatment responses and no cessation attributable to adverse effects. Bedaquiline could be considered for use with this age group for multidrug-resistant tuberculosis when treatment options are limited.
摘要
我们描述了 27 名年龄<18 岁的儿童和青少年，他们在接受耐多药结核病治疗时接受了贝达喹啉。我们报告了良好的治疗反应，没有因不良反应而停药。当治疗选择有限时，贝达喹啉可考虑用于该年龄组的耐多药结核病。
相似文献
1
Off-Label Use of Bedaquiline in Children and Adolescents with Multidrug-Resistant Tuberculosis.
Emerg Infect Dis. 2017 Oct;23(10):1711-3. doi: 10.3201/eid2310.170303. Epub 2017 Oct 17.
2
Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.
MMWR Recomm Rep. 2013 Oct 25;62(RR-09):1-12.
3
Bedaquiline: a novel antitubercular agent for the treatment of multidrug-resistant tuberculosis.
Pharmacotherapy. 2014 Nov;34(11):1187-97. doi: 10.1002/phar.1482. Epub 2014 Sep 9.
4
The use of bedaquiline to treat patients with multidrug-resistant tuberculosis and end-stage renal disease: A case report.
Int J Infect Dis. 2018 Nov;76:88-90. doi: 10.1016/j.ijid.2018.09.009. Epub 2018 Sep 19.
5
Tradeoffs in Introduction Policies for the Anti-Tuberculosis Drug Bedaquiline: A Model-Based Analysis.
PLoS Med. 2016 Oct 11;13(10):e1002142. doi: 10.1371/journal.pmed.1002142. eCollection 2016 Oct.
6
Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis.
Eur Respir J. 2016 Feb;47(2):564-74. doi: 10.1183/13993003.00724-2015. Epub 2015 Dec 2.
7
Bedaquiline: a novel diarylquinoline for multidrug-resistant tuberculosis.
Ann Pharmacother. 2014 Jan;48(1):107-15. doi: 10.1177/1060028013504087. Epub 2013 Nov 1.
8
Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis.
Eur Respir J. 2017 Mar 22;49(3). doi: 10.1183/13993003.01799-2016. Print 2017 Mar.
9
Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis.
Emerg Infect Dis. 2017 Oct;23(10):1718-21. doi: 10.3201/eid2310.170834. Epub 2017 Oct 17.
10
▼Bedaquiline for multidrug-resistant tuberculosis.
Drug Ther Bull. 2014 Nov;52(11):129-32. doi: 10.1136/dtb.2014.11.0291.
引用本文的文献
1
Treatment outcomes of bedaquiline-based longer oral antitubercular regimens in Indian children above five years of age.
Lung India. 2025 Jul 1;42(4):330-336. doi: 10.4103/lungindia.lungindia_609_24. Epub 2025 Jun 27.
2
Efficacy and safety of bedaquiline containing regimens in patients of drug-resistant tuberculosis: An updated systematic review and meta-analysis.
J Clin Tuberc Other Mycobact Dis. 2023 Dec 1;34:100405. doi: 10.1016/j.jctube.2023.100405. eCollection 2024 Feb.
3
Favourable outcomes in RR-TB patients using BPaL and other WHO-recommended second-line anti-TB drugs.
Int J Tuberc Lung Dis. 2023 Aug 1;27(8):599-605. doi: 10.5588/ijtld.22.0649.
4
Advances of new drugs bedaquiline and delamanid in the treatment of multi-drug resistant tuberculosis in children.
Front Cell Infect Microbiol. 2023 Jun 13;13:1183597. doi: 10.3389/fcimb.2023.1183597. eCollection 2023.
5
Bedaquiline-containing regimens and multidrug-resistant tuberculosis: a systematic review and meta-analysis.
J Bras Pneumol. 2022 May 30;48(2):e20210384. doi: 10.36416/1806-3756/e20210384. eCollection 2022.
6
Treatment of Rifampicin-Resistant Tuberculosis Disease and Infection in Children: Key Updates, Challenges and Opportunities.
Pathogens. 2022 Mar 23;11(4):381. doi: 10.3390/pathogens11040381.
7
Bedaquiline for multidrug-resistant TB in paediatric patients.
Int J Tuberc Lung Dis. 2021 Sep 1;25(9):716-724. doi: 10.5588/ijtld.21.0022.
8
Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Children: The Role of Bedaquiline and Delamanid.
Microorganisms. 2021 May 17;9(5):1074. doi: 10.3390/microorganisms9051074.
9
Characterization of Genomic Variants Associated with Resistance to Bedaquiline and Delamanid in Naive Mycobacterium tuberculosis Clinical Strains.
J Clin Microbiol. 2020 Oct 21;58(11). doi: 10.1128/JCM.01304-20.
10
Investigation of genus as a new source of antimycobaterial agents.
Future Sci OA. 2020 May 29;6(7):FSO587. doi: 10.2144/fsoa-2020-0018.
本文引用的文献
1
New and Repurposed Drugs for Pediatric Multidrug-Resistant Tuberculosis. Practice-based Recommendations.
Am J Respir Crit Care Med. 2017 May 15;195(10):1300-1310. doi: 10.1164/rccm.201606-1227CI.
2
Global burden of drug-resistant tuberculosis in children: a mathematical modelling study.
Lancet Infect Dis. 2016 Oct;16(10):1193-1201. doi: 10.1016/S1473-3099(16)30132-3. Epub 2016 Jun 21.
3
Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challenges.
Eur Respir J. 2016 Sep;48(3):938-43. doi: 10.1183/13993003.00705-2016. Epub 2016 Jun 23.
4
Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR-TB cohort study.
Int J Tuberc Lung Dis. 2016 Feb;20(2):177-86. doi: 10.5588/ijtld.15.0962.
5
Incidence of multidrug-resistant tuberculosis disease in children: systematic review and global estimates.
Lancet. 2014 May 3;383(9928):1572-9. doi: 10.1016/S0140-6736(14)60195-1. Epub 2014 Mar 24.
6
Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.
MMWR Recomm Rep. 2013 Oct 25;62(RR-09):1-12.
7
High treatment success in children treated for multidrug-resistant tuberculosis: an observational cohort study.
Thorax. 2014 May;69(5):458-64. doi: 10.1136/thoraxjnl-2013-203900. Epub 2013 Sep 24.
8
Hearing loss in children treated for multidrug-resistant tuberculosis.
J Infect. 2013 Apr;66(4):320-9. doi: 10.1016/j.jinf.2012.09.002. Epub 2012 Sep 6.
Zotero 插件